Skip to main content
Erschienen in: Reactions Weekly 1/2014

01.10.2014 | Media release

Naloxegol approved for opioid-induced constipation

Erschienen in: Reactions Weekly | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

The US FDA has approved naloxegol (MOVANTIK) for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, according to an AstraZeneca media release. It is expected to be available to patients in the first half of 2015. …
Literatur
Zurück zum Zitat AstraZeneca. FDA Approves MOVANTIK(Tm) (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain. Media Release : 16 Sep 2014. Available from: URL: http://www.astrazeneca-us.com AstraZeneca. FDA Approves MOVANTIK(Tm) (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain. Media Release : 16 Sep 2014. Available from: URL: http://​www.​astrazeneca-us.​com
Metadaten
Titel
Naloxegol approved for opioid-induced constipation
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2014
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-014-3808-8

Weitere Artikel der Ausgabe 1/2014

Reactions Weekly 1/2014 Zur Ausgabe

Case report

Metformin

Case report

Heparin